- Phase I/IIa study of PM8001, a bifunctional fusion protein targeting PD-L1 and TGF-?, in patients with advanced tumorsGuo, Ye; Liu, Baogang; Lv, Dongqing; Cheng, Ying; Zhou, Tong; Zhong, Yahua; Hu, Changlu; Chen, Gang; Wu, Xiaohua; Yin, Yongmei; Wu, Lihua; Chen, Zhendong; Luo, Hong; Zhou, Xiaohong; Qin, Yanru; Yang, Yuxing; Luo, Suxia; Ma, Yanjie; Li, Yalin; Hu, GuoqiangAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.被引 5
- Phase I/II combination study of tifcemalimab with toripalimab in patients with refractory extensive stage small cell lung cancer (ES-SCLC)Cheng, Ying; Wang, Jie; Yu, Yan; Wang, Qiming; Yang, Runxiang; Lv, Dongqing; Xia, Bing; Yi, Tienan; Li, Chong; Wang, Xicheng; Zhang, Wei; Han, Liang; Liu, Xiaoqing; Shen, Minjie; Xu, Jing; Xue, Peng; Wang, WeihuaAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory researchZhao, Y.; Liu, J.; Li, X.; Li, Y.; Pu, H.; Wang, X.; Yang, M.; Bai, S.; Guo, L.; Zhao, L.; Zhang, M.; Zhao, H.; Xu, S.; Wang, Y.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
会议论文
A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
9阅读
